Trial Profile
A Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Intravenous Doses of 3 Dose Levels of CAT-354 in Subjects With Moderate Asthma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 04 May 2017
Price :
$35
*
At a glance
- Drugs Tralokinumab (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors MedImmune
- 22 Mar 2017 Status changed from completed to discontinued because Study recruitment was terminated before the planned number of subjects was enrolled in CAT-354 10 mg/kg group due to the slow recruitment rate. .
- 11 Sep 2009 New trial record